Literature DB >> 10594558

Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

M Anttila1, M Voutilainen, V Jäntti, J Eskola, H Käyhty.   

Abstract

The contribution of serotype-specific IgG concentration, subclasses, and avidity to opsonophagocytic activity (OPA) against Streptococcus pneumoniae (Pnc) was evaluated in sera of adults and infants immunized with different pneumococcal vaccines. Antibody concentrations and avidities were measured by enzyme immunoassay (EIA) and OPAs by killing assay of Pnc. The most important factor contributing positively to OPA was the specific IgG level. In infants, a tendency to negative correlation was found between the concentration needed for killing of bacteria and avidity, suggesting that less antibodies of high rather than low avidity were required for killing. No such correlation was seen in adults. However, in adults the avidity was high already before vaccination and the variation was narrow. Thus, avidity was probably not a limiting factor influencing OPA. The effect of IgG2/IgG1 ratio on OPA was mostly negative but insignificant.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594558      PMCID: PMC1905437          DOI: 10.1046/j.1365-2249.1999.01077.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines.

Authors:  A Soininen; I Seppälä; T Nieminen; J Eskola; H Käyhty
Journal:  Vaccine       Date:  1999-04-09       Impact factor: 3.641

2.  Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF.

Authors:  A Soininen; I Seppälä; T Wuorimaa; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

3.  Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid.

Authors:  M Korkeila; H Lehtonen; H Ahman; O Leroy; J Eskola; H Käyhty
Journal:  Vaccine       Date:  2000-01-18       Impact factor: 3.641

4.  Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum.

Authors:  T Nieminen; J Eskola; H Käyhty
Journal:  Vaccine       Date:  1998-04       Impact factor: 3.641

5.  Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.

Authors:  M Anttila; J Eskola; H Ahman; H Käyhty
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

6.  Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood.

Authors:  M Anttila; J Eskola; H Ahman; H Käyhty
Journal:  Vaccine       Date:  1999-04-09       Impact factor: 3.641

7.  Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory.

Authors:  H Ahman; H Käyhty; H Lehtonen; O Leroy; J Froeschle; J Eskola
Journal:  Pediatr Infect Dis J       Date:  1998-03       Impact factor: 2.129

8.  Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.

Authors:  Y Schlesinger; D M Granoff
Journal:  JAMA       Date:  1992-03-18       Impact factor: 56.272

9.  A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics.

Authors:  M C Steinhoff; K Edwards; H Keyserling; M L Thoms; C Johnson; D Madore; D Hogerman
Journal:  Pediatr Infect Dis J       Date:  1994-05       Impact factor: 2.129

10.  Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae.

Authors:  G Vitharsson; I Jónsdóttir; S Jónsson; H Valdimarsson
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

View more
  40 in total

Review 1.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Authors:  Anu Soininen; Maijastiina Karpala; Sirkka-Liisa Wahlman; Hannele Lehtonen; Helena Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

3.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.

Authors:  Nina Ekström; Heidi Ahman; Jouko Verho; Jukka Jokinen; Merja Väkeväinen; Terhi Kilpi; Helena Käyhty
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.

Authors:  Shannon L Harris; How Tsao; Lindsey Ashton; David Goldblatt; Philip Fernsten
Journal:  Clin Vaccine Immunol       Date:  2007-02-07

6.  Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Authors:  F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland
Journal:  Vaccine       Date:  2010-10-31       Impact factor: 3.641

7.  Avidity of antibodies against infecting pneumococcal serotypes increases with age and severity of disease.

Authors:  Amelieke J H Cremers; Jonneke Lut; Peter W M Hermans; Jacques F Meis; Marien I de Jonge; Gerben Ferwerda
Journal:  Clin Vaccine Immunol       Date:  2014-04-23

8.  Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease.

Authors:  Roberto Adamo; Alberto Nilo; Carole Harfouche; Barbara Brogioni; Simone Pecetta; Giulia Brogioni; Evita Balducci; Vittoria Pinto; Sara Filippini; Elena Mori; Marta Tontini; Maria Rosaria Romano; Paolo Costantino; Francesco Berti
Journal:  Glycoconj J       Date:  2014-09-26       Impact factor: 2.916

9.  Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable?

Authors:  M Väkeväinen; W Jansen; E Saeland; I Jonsdottir; H Snippe; A Verheul; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

10.  Screening one bead one compound libraries against serum using a flow cytometer: Determination of the minimum antibody concentration required for ligand discovery.

Authors:  Osayemwenre Erharuyi; Scott Simanski; Patrick J McEnaney; Thomas Kodadek
Journal:  Bioorg Med Chem Lett       Date:  2018-01-31       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.